Market Overview:
The global respiratory syncytial virus (RSV) therapeutics market is expected to grow at a CAGR of XX% during the forecast period 2018-2030. The market growth can be attributed to the increasing incidence of RSV infections, rising demand for novel therapies, and growing awareness about RSV infections. Based on type, the global respiratory syncytial virus (RSV) therapeutics market is segmented into palivizumab, ribavirin, and others. Palivizumab held a dominant share in 2016 and is expected to maintain its dominance during the forecast period. This can be attributed to its high efficacy in preventing severe RSV infection in high-risk patients such as those with chronic lung diseases or premature infants. Based on application, the global respiratory syncytial virus (RSV) therapeutics market is segmented into hospital pharmacies, drug stores, retail pharmacies, and others. Hospital pharmacies held a major share of the market in 2016 owing to increased use of palivizumab for prophylaxis against severe RSV infection among high-risk patients admitted in hospitals.
 Therapeutics Industry Outlook.svg)
Product Definition:
Respiratory syncytial virus (RSV) is a common and highly contagious virus that causes severe respiratory illness in children and adults. RSV is the leading cause of bronchiolitis, an infection of the small airways in the lungs, and pneumonia in young children. The incidence of RSV infection peaks during winter and early spring months. RSV also can cause serious illness in older adults, including hospitalization and even death. There is no specific cure for RSV infection; treatment focuses on relieving symptoms. However, there are effective therapies available to prevent or reduce the severity of disease caused by this virus.
Palivizumab:
Palivizumab is a humanized monoclonal antibody designed for the treatment of respiratory syncytial virus infections. It works by binding to the protein receptor on cells that results in inhibition of viral infection.
Ribavirin:
Ribavirin is an antiviral medication used for the treatment of chronic RSV infections in infants and children. It is also used as prophylactic treatment to prevent the occurrence of such infections. The drug was developed by Hoffmann-La Roche Ltd., and S.D. Pharmaceuticals, Inc., which later became part of Novartis AG, has a global marketing authorization for it till date.
Application Insights:
Based on application, the global respiratory syncytial virus therapeutics market is segmented into hospital pharmacies, drug stores, retail pharmacies and others. The other applications include hospitals and clinics that administer palivizumab as an outpatient treatment or in combination with ribavirin for the treatment of RSV infection in hospitalized patients.
The hospital pharmacies segment dominated the overall industry with a share of over 60% in 2021 owing to increasing awareness about preventive measures against Respiratory Syncytial Virus (RSV). In addition, growing investments by governments to improve healthcare infrastructure at a domestic level is expected to positively impact growth. As per WHO estimates from 2015-2016; over 1 billion people still lack access to basic health services which includes diagnosis and effective treatments for common diseases such as diabetes & cancer worldwide.
Regional Analysis:
North America dominated the global market in 2018 and is expected to maintain its position during the forecast period. The presence of key players, favorable reimbursement policies, rising healthcare expenditure & government initiatives are some of the factors contributing to its growth. In addition, increasing number of hospitalizations due to various infectious diseases is also anticipated to boost demand for therapeutics in this region.
Asia Pacific is estimated to be fastest-growing region over the forecast period owing with growing target population base coupled with rising incidence rate RSV infections especially in developing countries such as India and China which makes it a lucrative market for global players looking forward invest or launch new products.
Growth Factors:
- Increasing incidence of respiratory syncytial virus (RSV) infection: The global incidence of RSV infection is increasing due to the increase in the number of susceptible population, such as elderly and immunocompromised patients. This is expected to drive the demand for RSV therapeutics products.
- Growing awareness about RSV infections: There is a growing awareness among healthcare professionals and patients about the symptoms, diagnosis, and treatment of RSV infections. This is likely to boost the demand for RSV therapeutics products in coming years.
- Technological advancements in diagnostics: The technological advancements in diagnostics are helping healthcare professionals to detect early onset of respiratory syncytial virus (RSV) infection and initiate appropriate treatment accordingly thereby reducing its severity and mortality rates associated with it .This is anticipated to fuel growth prospects for this market during forecast period
Scope Of The Report
Report Attributes
Report Details
Report Title
Respiratory Syncytial Virus(RSV) Therapeutics Market Research Report
By Type
Palivizumab, Ribavirin, Others
By Application
Global Respiratory Syncytial Virus(RSV) Therapeutics Market Share by Sale Channel: 2016 VS 2021 VS 2027, Hospital Pharmacies, Drug Stores, Retail Pharmacies, Others
By Companies
Roche, AstraZeneca, Merck, AbbVie, Bausch Health, GlaxoSmithKline, ReViral, Gilead Sciences, Teva Pharmaceutical
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
143
Number of Tables & Figures
101
Customization Available
Yes, the report can be customized as per your need.
Global Respiratory Syncytial Virus(RSV) Therapeutics Market Report Segments:
The global Respiratory Syncytial Virus(RSV) Therapeutics market is segmented on the basis of:
Types
Palivizumab, Ribavirin, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Global Respiratory Syncytial Virus(RSV) Therapeutics Market Share by Sale Channel: 2016 VS 2021 VS 2027, Hospital Pharmacies, Drug Stores, Retail Pharmacies, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Roche
- AstraZeneca
- Merck
- AbbVie
- Bausch Health
- GlaxoSmithKline
- ReViral
- Gilead Sciences
- Teva Pharmaceutical
 Therapeutics Market Overview.svg)
Highlights of The Respiratory Syncytial Virus(RSV) Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Palivizumab
- Ribavirin
- Others
- By Application:
- Global Respiratory Syncytial Virus(RSV) Therapeutics Market Share by Sale Channel: 2016 VS 2021 VS 2027
- Hospital Pharmacies
- Drug Stores
- Retail Pharmacies
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Respiratory Syncytial Virus(RSV) Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Therapeutics Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Respiratory syncytial virus (RSV) therapeutics are medications used to treat RSV infections. These medications can help reduce the severity and duration of RSV infections, as well as prevent new RSV infections from occurring.
Some of the major companies in the respiratory syncytial virus(rsv) therapeutics market are Roche, AstraZeneca, Merck, AbbVie, Bausch Health, GlaxoSmithKline, ReViral, Gilead Sciences, Teva Pharmaceutical.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Respiratory Syncytial Virus(RSV) Therapeutics Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Respiratory Syncytial Virus(RSV) Therapeutics Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Respiratory Syncytial Virus(RSV) Therapeutics Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Respiratory Syncytial Virus(RSV) Therapeutics Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Respiratory Syncytial Virus(RSV) Therapeutics Market Size & Forecast, 2018-2028
4.5.1 Respiratory Syncytial Virus(RSV) Therapeutics Market Size and Y-o-Y Growth
4.5.2 Respiratory Syncytial Virus(RSV) Therapeutics Market Absolute $ Opportunity
Chapter 5 Global Respiratory Syncytial Virus(RSV) Therapeutics Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Respiratory Syncytial Virus(RSV) Therapeutics Market Size Forecast by Type
5.2.1 Palivizumab
5.2.2 Ribavirin
5.2.3 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Respiratory Syncytial Virus(RSV) Therapeutics Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Respiratory Syncytial Virus(RSV) Therapeutics Market Size Forecast by Applications
6.2.1 Global Respiratory Syncytial Virus(RSV) Therapeutics Market Share by Sale Channel: 2016 VS 2021 VS 2027
6.2.2 Hospital Pharmacies
6.2.3 Drug Stores
6.2.4 Retail Pharmacies
6.2.5 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Respiratory Syncytial Virus(RSV) Therapeutics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Respiratory Syncytial Virus(RSV) Therapeutics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Respiratory Syncytial Virus(RSV) Therapeutics Analysis and Forecast
9.1 Introduction
9.2 North America Respiratory Syncytial Virus(RSV) Therapeutics Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Respiratory Syncytial Virus(RSV) Therapeutics Market Size Forecast by Type
9.6.1 Palivizumab
9.6.2 Ribavirin
9.6.3 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Respiratory Syncytial Virus(RSV) Therapeutics Market Size Forecast by Applications
9.10.1 Global Respiratory Syncytial Virus(RSV) Therapeutics Market Share by Sale Channel: 2016 VS 2021 VS 2027
9.10.2 Hospital Pharmacies
9.10.3 Drug Stores
9.10.4 Retail Pharmacies
9.10.5 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Respiratory Syncytial Virus(RSV) Therapeutics Analysis and Forecast
10.1 Introduction
10.2 Europe Respiratory Syncytial Virus(RSV) Therapeutics Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Respiratory Syncytial Virus(RSV) Therapeutics Market Size Forecast by Type
10.6.1 Palivizumab
10.6.2 Ribavirin
10.6.3 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Respiratory Syncytial Virus(RSV) Therapeutics Market Size Forecast by Applications
10.10.1 Global Respiratory Syncytial Virus(RSV) Therapeutics Market Share by Sale Channel: 2016 VS 2021 VS 2027
10.10.2 Hospital Pharmacies
10.10.3 Drug Stores
10.10.4 Retail Pharmacies
10.10.5 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Respiratory Syncytial Virus(RSV) Therapeutics Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Respiratory Syncytial Virus(RSV) Therapeutics Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Respiratory Syncytial Virus(RSV) Therapeutics Market Size Forecast by Type
11.6.1 Palivizumab
11.6.2 Ribavirin
11.6.3 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Respiratory Syncytial Virus(RSV) Therapeutics Market Size Forecast by Applications
11.10.1 Global Respiratory Syncytial Virus(RSV) Therapeutics Market Share by Sale Channel: 2016 VS 2021 VS 2027
11.10.2 Hospital Pharmacies
11.10.3 Drug Stores
11.10.4 Retail Pharmacies
11.10.5 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Respiratory Syncytial Virus(RSV) Therapeutics Analysis and Forecast
12.1 Introduction
12.2 Latin America Respiratory Syncytial Virus(RSV) Therapeutics Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Respiratory Syncytial Virus(RSV) Therapeutics Market Size Forecast by Type
12.6.1 Palivizumab
12.6.2 Ribavirin
12.6.3 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Respiratory Syncytial Virus(RSV) Therapeutics Market Size Forecast by Applications
12.10.1 Global Respiratory Syncytial Virus(RSV) Therapeutics Market Share by Sale Channel: 2016 VS 2021 VS 2027
12.10.2 Hospital Pharmacies
12.10.3 Drug Stores
12.10.4 Retail Pharmacies
12.10.5 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Respiratory Syncytial Virus(RSV) Therapeutics Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Respiratory Syncytial Virus(RSV) Therapeutics Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Respiratory Syncytial Virus(RSV) Therapeutics Market Size Forecast by Type
13.6.1 Palivizumab
13.6.2 Ribavirin
13.6.3 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Respiratory Syncytial Virus(RSV) Therapeutics Market Size Forecast by Applications
13.10.1 Global Respiratory Syncytial Virus(RSV) Therapeutics Market Share by Sale Channel: 2016 VS 2021 VS 2027
13.10.2 Hospital Pharmacies
13.10.3 Drug Stores
13.10.4 Retail Pharmacies
13.10.5 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Respiratory Syncytial Virus(RSV) Therapeutics Market: Competitive Dashboard
14.2 Global Respiratory Syncytial Virus(RSV) Therapeutics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Roche
14.3.2 AstraZeneca
14.3.3 Merck
14.3.4 AbbVie
14.3.5 Bausch Health
14.3.6 GlaxoSmithKline
14.3.7 ReViral
14.3.8 Gilead Sciences
14.3.9 Teva Pharmaceutical
